Kane Biotech Inc. (CVE:KNE – Get Free Report)’s stock price traded down 14.3% during trading on Tuesday . The company traded as low as C$0.03 and last traded at C$0.03. 101,404 shares changed hands during trading, a decline of 46% from the average session volume of 187,188 shares. The stock had previously closed at C$0.04.
Kane Biotech Trading Down 14.3%
The company has a debt-to-equity ratio of -308.66, a quick ratio of 0.39 and a current ratio of 0.68. The company has a market cap of C$5.46 million, a P/E ratio of -1.50 and a beta of 1.03. The business has a fifty day simple moving average of C$0.03 and a 200 day simple moving average of C$0.04.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Articles
- Five stocks we like better than Kane Biotech
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
- The Pentagon’s AI Pivot Supercharges Defense Stocks
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
